01—Abstract
Summary
Summary of the 10-Q filed October 29, 2024. Cited figures are marked; the original filing is the authoritative source.
Tenet Healthcare Corporation's Form 10-Q for the quarter ended September 30, 2024 shows a sharp rise in reported profitability driven mainly by hospital divestitures.
Net income for the nine months ended September 30, 2024 was $3.492 billiona, versus $855 million a year earlier, and net operating revenues were $15.593 billion, up from $15.169 billion. Net income available to Tenet common shareholders was $2.882 billion for the nine months, with diluted EPS of $29.27, compared with $3.41 in the prior-year period. The results were lifted by net gains on sales, consolidation and deconsolidation of facilities of $2.906 billion, including a $1.677 billion gain on the sale of the South Carolina hospitals and gains on the California and Alabama hospital sales.
Cash and cash equivalents rose to $4.094 billionb at September 30, 2024, from $1.228 billion at December 31, 2023, reflecting $4.965 billion of proceeds from sales of facilities and other assets during the nine months. The company used cash to redeem all $2.100 billion of its 4.875% senior secured first lien notes due 2026, and repurchased $672 million of common stock under its share repurchase programs. Total long-term debt, including current portion, was $12.871 billion, down from $15.002 billion.
The filing states a ratio of total long-term debt, net of cash, to Adjusted EBITDA of 2.22xc using the last twelve months of Adjusted EBITDA. Operationally, Hospital Operations net operating revenues declined 0.5% for the nine months as a result of divestitures, while the Ambulatory Care segment grew 17.5% on acquisitions. Management highlighted that excluding the divested hospitals, Hospital Operations revenue rose 8.5% for the nine months.
The filing also notes a $182 milliond balance of advances from managed care payers tied to the February 2024 Change Healthcare cyberattack, which the company expects to repay substantially in the fourth quarter of 2024. In late September 2024, Hurricane Helene damaged a North Carolina factory that produces sterile IV fluids, creating uncertainty about a national IV fluid shortage that could affect patient volumes or revenues.
02—Key points
Key Highlights
- Net income for the nine months ended September 30, 2024 was $3.492 billion, versus $855 million in the prior-year period, and diluted EPS was $29.27 versus $3.41.
- Net gains on sales, consolidation and deconsolidation of facilities totaled $2.906 billion for the nine months, including a $1.677 billion pre-tax gain on the sale of the SC Hospitals.
- Net operating revenues were $15.593 billion for the nine months, up from $15.169 billion; Ambulatory Care revenues rose 17.5% while Hospital Operations revenues decreased 0.5%.
- Cash and cash equivalents increased to $4.094 billion from $1.228 billion at December 31, 2023, supported by $4.965 billion of proceeds from sales of facilities and other assets.
- Total long-term debt, including current portion, fell to $12.871 billion from $15.002 billion after the $2.100 billion redemption of 2026 senior secured first lien notes.
- The company repurchased $672 million of common stock in the nine months, and the 2024 share repurchase program had $1.376 billion remaining at September 30, 2024.
- Advances of $182 million from managed care payers related to the Change Healthcare cyberattack remained outstanding, with a significant portion expected to be repaid in the fourth quarter of 2024.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 29, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $5.13B$5.07B | +1.2% |
| Operating Income | $1.09B$568.00M | +91.7% |
| Net Income | $472.00M$101.00M | +367.3% |
| EPS (Basic) | $4.93$0.99 | +398.0% |
| EPS (Diluted) | $4.89$0.94 | +420.2% |
| Shares Outstanding (Basic) | 95.67M101.54M | −5.8% |
| Shares Outstanding (Diluted) | 96.65M104.42M | −7.4% |
05—Questions
Frequently Asked Questions
How much of the nine-month profit increase came from one-time gains on facility sales?
The filing reports net gains on sales, consolidation and deconsolidation of facilities of $2.906 billion for the nine months ended September 30, 2024, compared with $12 million in the prior-year period. Income before income taxes was $4.593 billion, versus $1.098 billion a year earlier, so these gains account for most of the increase.
What drove the decline in Hospital Operations revenue, and how did the company describe underlying performance?
Hospital Operations net operating revenues decreased $63 million, or 0.5%, for the nine months, primarily due to the sales of the Divested Hospitals. Excluding the impact of those sales, the filing states Hospital Operations revenues increased $941 million, or 8.5%, driven by a more favorable payer mix, higher patient volumes and acuity, Medicaid supplemental revenue growth and negotiated commercial rate increases.
How did the company change its debt profile during 2024?
Total long-term debt, including the current portion, declined to $12.871 billion at September 30, 2024 from $15.002 billion at December 31, 2023. The company redeemed all $2.100 billion of its 4.875% senior secured first lien notes due 2026 in March 2024 using cash on hand, and recorded an $8 million loss on early extinguishment of debt. The company had no cash borrowings outstanding under its $1.500 billion Credit Agreement.
What are the near-term cash obligations and risks mentioned in the filing?
The company reported a current income tax payable of $826 million at September 30, 2024, primarily from taxes associated with gains on the divested hospitals, and noted IRS relief deferring federal tax payments for affected Texas businesses until November 2024. It also had $182 million of managed care payer advances outstanding that it expects to repay largely in the fourth quarter of 2024. The filing further notes the uncertain timeline for resolving the national IV fluid shortage following Hurricane Helene, which could affect patient volumes or net operating revenues.
06—Continue